Stock Movers: Hershey, Hims & Hers, Warner Bros. (Podcast)

Hershey (HSY) shares climbed 5.3% after Goldman Sachs double-upgraded the stock to "buy," citing improving market-share trends, strong pricing power expected to drive FY26 growth, and cost pressures now being factored into expectations. Conversely, Hims & Hers Health (HIMS) shares slid following an FDA warning letter concerning false or misleading claims about compounded semaglutide products. Warner Bros. Discovery (WBD) also declined after TD Cowen downgraded the stock to "hold" from "buy," attributing its recent rally to unsubstantiated acquisition rumors and highlighting significant downside risk if a bid fails to materialize.

Analysis

Divergent catalysts drove significant stock movements for three key companies. Hershey (HSY) shares rallied as much as 5.3% following a double-upgrade to 'buy' from Goldman Sachs, which cited improving market-share trends after previous losses. The bank's analyst noted that cost pressures from cocoa and tariffs are now adequately reflected in expectations, creating a more compelling risk profile, and that recent pricing actions are poised to drive outsized growth in FY26. Conversely, Hims & Hers Health (HIMS) experienced a share price decline after the FDA issued a warning letter, alleging that the telehealth company's online claims regarding its compounded semaglutide products were false or misleading, introducing a significant regulatory headwind. Meanwhile, Warner Bros. Discovery (WBD) shares fell after TD Cowen downgraded the stock to 'hold' from 'buy'. The downgrade was attributed to the stock's recent surge, which the analyst deemed speculative and driven by an unsubstantiated report of a potential acquisition bid, creating an unfavorable risk-reward scenario with shares having moved 'well beyond' a $14 price target and facing a potential drop to the $11-$12 range if a bid fails to materialize.

Key Decisions for Investors

• Given the Goldman Sachs upgrade, investors may view Hershey (HSY) more favorably, as improving market-share trends and priced-in cost headwinds suggest a potential inflection point for the company.
• Investors in Hims & Hers Health (HIMS) should exercise caution, as the FDA warning letter introduces significant regulatory risk and potential reputational damage that could impact the growth of its key weight-loss offerings.
• For Warner Bros. Discovery (WBD), the TD Cowen downgrade highlights the speculative nature of its current valuation; investors should consider the elevated downside risk, as the stock's rally is tied to unconfirmed M&A rumors rather than fundamental improvements.